William H. Sauer, MD, FHRS, CCDS of Brigham and Women's Hospital, is joined by Uyanga Batnyam, MD of the University of Washington and Usha B. Tedrow, MD, MS, FHRS of Brigham and Women`s Hospital to discuss the risks of radiofrequency catheter ablation for ventricular arrhythmias include emboli and bleeding complications but data on antithrombotic regimens are limited and guidelines do not specify a systematic approach. This study sought to assess embolic and bleeding complications in relation to pre- and postperiprocedure antithrombotic regimens. Stroke is a rare complication of radiofrequency catheter ablation for ventricular arrhythmia using ASA 325 mg/d as a minimal postprocedure regimen with more potent regimens for selected patients.

https://www.hrsonline.org/education/TheLead https://www.jacc.org/doi/abs/10.1016/j.jacep.2023.10.011

Host Disclosure(s): W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic

Contributor Disclosure(s): U. Batnyam: No relevant financial relationships with ineligible companies to disclose.  U. Tedrow: Honoraria/Speaking/Consulting: Medtronic, Inc., Biosense Webster, Inc., St. Jude Medical, Thermedical, Boston Scientific, Baylis Medical Company

“This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365 https://www.heartrhythm365.org/URL/TheLeadEpisode49